Posted by Michael Wonder on 30 Jan 2022
Baqsimi (nasal glucagon) rescue treatment for severe hypoglycaemia now covered in Ontario
28 January 2022 - Lilly Canada is pleased to announce that as of 31 January 2022, Baqsimi (glucagon nasal powder) is now covered under the Ontario Drug Benefit Formulary, as a Limited Use benefit.
Baqsimi is indicated for the treatment of severe hypoglycaemic reactions in people with insulin-treated diabetes mellitus 4 years old and above when impaired consciousness precludes oral carbohydrates.
